Conjustar announced the completion of ￥100 million Pre-A+ round of financing

Conjustar announced the completion of ￥100 million  Pre-A+ round of financing. This round of financing was led by Fosun health Capital New Drug Innovation Fund of Fosun Pharmaceutical, and co-invested by Hengqin Venture Capital and Shenzhen Qianhai Liyuan.

This round of financing will provide important financial support for the product research and development of Conjustar, to accelerate the clinical trials of SC-101 and SC-102, and research more XDC pipeline .